Linked Life Data

16184411

Source:http://linkedlifedata.com/resource/pubmed/id/16184411

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16184411rdf:typepubmed:Citationlld:pubmed
pubmed-article:16184411lifeskim:mentionsumls-concept:C0013227lld:lifeskim
pubmed-article:16184411lifeskim:mentionsumls-concept:C0007634lld:lifeskim
pubmed-article:16184411lifeskim:mentionsumls-concept:C0010453lld:lifeskim
pubmed-article:16184411lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:16184411lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:16184411lifeskim:mentionsumls-concept:C0026724lld:lifeskim
pubmed-article:16184411lifeskim:mentionsumls-concept:C0162638lld:lifeskim
pubmed-article:16184411lifeskim:mentionsumls-concept:C1704242lld:lifeskim
pubmed-article:16184411lifeskim:mentionsumls-concept:C0012854lld:lifeskim
pubmed-article:16184411lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:16184411lifeskim:mentionsumls-concept:C0004083lld:lifeskim
pubmed-article:16184411lifeskim:mentionsumls-concept:C2249823lld:lifeskim
pubmed-article:16184411lifeskim:mentionsumls-concept:C2003941lld:lifeskim
pubmed-article:16184411lifeskim:mentionsumls-concept:C0237477lld:lifeskim
pubmed-article:16184411lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:16184411lifeskim:mentionsumls-concept:C0069562lld:lifeskim
pubmed-article:16184411lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:16184411pubmed:dateCreated2005-9-26lld:pubmed
pubmed-article:16184411pubmed:abstractTextRebamipide, a gastromucosal protective drug, suppresses indomethacin-induced gastropathy in humans and rodents. Effects of rebamipide on gene expression in indomethacin-treated gastric mucosal cells (RGM1) were investigated using high-density oligonucleotide arrays. Indomethacin induced apoptosis in RGM1 cells in a dose-dependent manner. Rebamipide pretreatment significantly reduced indomethacin-induced apoptosis. We used gene expression profiling on high-density oligonucleotide probe arrays to characterize the transcriptional response of RGM1 cells to indomethacin treatment for 6 hr. Of the 8,799 probes examined, 717 (8.1%) were induced (400 probes) or repressed (317 probes) at least 1.5-fold. Among the 158 genes that were induced by indomethacin at least 2.0-fold, four genes that were down-regulated by rebamipide at least 2.0-fold are listed: growth arrest and DNA-damage-inducible 45 alpha (GADD 45 alpha), golgi SNAP receptor complex member 1, iodothyronine deiodinases, and transcription factor 8. Real time-PCR confirmed GADD 45 alpha expression and its inhibition by rebamipide. Inhibition of apoptosis-related genes is possibly important for the cytoprotective effect of rebamipide against indomethacin-induced gastric mucosal cell injury.lld:pubmed
pubmed-article:16184411pubmed:languageenglld:pubmed
pubmed-article:16184411pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16184411pubmed:citationSubsetAIMlld:pubmed
pubmed-article:16184411pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16184411pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16184411pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16184411pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16184411pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16184411pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16184411pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16184411pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16184411pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16184411pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16184411pubmed:statusMEDLINElld:pubmed
pubmed-article:16184411pubmed:monthOctlld:pubmed
pubmed-article:16184411pubmed:issn0163-2116lld:pubmed
pubmed-article:16184411pubmed:authorpubmed-author:YoshikawaTosh...lld:pubmed
pubmed-article:16184411pubmed:authorpubmed-author:MatsuiHirofum...lld:pubmed
pubmed-article:16184411pubmed:authorpubmed-author:IchikawaHiros...lld:pubmed
pubmed-article:16184411pubmed:authorpubmed-author:ShimozawaMako...lld:pubmed
pubmed-article:16184411pubmed:authorpubmed-author:YoshidaNorima...lld:pubmed
pubmed-article:16184411pubmed:authorpubmed-author:NaitoYujiYlld:pubmed
pubmed-article:16184411pubmed:authorpubmed-author:TakagiTomohis...lld:pubmed
pubmed-article:16184411pubmed:authorpubmed-author:HandaOsamuOlld:pubmed
pubmed-article:16184411pubmed:authorpubmed-author:KurodaMasaaki...lld:pubmed
pubmed-article:16184411pubmed:authorpubmed-author:KokuraSatoshi...lld:pubmed
pubmed-article:16184411pubmed:authorpubmed-author:KatadaKazuhir...lld:pubmed
pubmed-article:16184411pubmed:authorpubmed-author:MizushimaKats...lld:pubmed
pubmed-article:16184411pubmed:authorpubmed-author:KajikawaHirok...lld:pubmed
pubmed-article:16184411pubmed:issnTypePrintlld:pubmed
pubmed-article:16184411pubmed:volume50 Suppl 1lld:pubmed
pubmed-article:16184411pubmed:ownerNLMlld:pubmed
pubmed-article:16184411pubmed:authorsCompleteYlld:pubmed
pubmed-article:16184411pubmed:paginationS104-12lld:pubmed
pubmed-article:16184411pubmed:dateRevised2005-11-17lld:pubmed
pubmed-article:16184411pubmed:meshHeadingpubmed-meshheading:16184411...lld:pubmed
pubmed-article:16184411pubmed:meshHeadingpubmed-meshheading:16184411...lld:pubmed
pubmed-article:16184411pubmed:meshHeadingpubmed-meshheading:16184411...lld:pubmed
pubmed-article:16184411pubmed:meshHeadingpubmed-meshheading:16184411...lld:pubmed
pubmed-article:16184411pubmed:meshHeadingpubmed-meshheading:16184411...lld:pubmed
pubmed-article:16184411pubmed:meshHeadingpubmed-meshheading:16184411...lld:pubmed
pubmed-article:16184411pubmed:meshHeadingpubmed-meshheading:16184411...lld:pubmed
pubmed-article:16184411pubmed:meshHeadingpubmed-meshheading:16184411...lld:pubmed
pubmed-article:16184411pubmed:meshHeadingpubmed-meshheading:16184411...lld:pubmed
pubmed-article:16184411pubmed:meshHeadingpubmed-meshheading:16184411...lld:pubmed
pubmed-article:16184411pubmed:meshHeadingpubmed-meshheading:16184411...lld:pubmed
pubmed-article:16184411pubmed:meshHeadingpubmed-meshheading:16184411...lld:pubmed
pubmed-article:16184411pubmed:meshHeadingpubmed-meshheading:16184411...lld:pubmed
pubmed-article:16184411pubmed:meshHeadingpubmed-meshheading:16184411...lld:pubmed
pubmed-article:16184411pubmed:meshHeadingpubmed-meshheading:16184411...lld:pubmed
pubmed-article:16184411pubmed:meshHeadingpubmed-meshheading:16184411...lld:pubmed
pubmed-article:16184411pubmed:meshHeadingpubmed-meshheading:16184411...lld:pubmed
pubmed-article:16184411pubmed:meshHeadingpubmed-meshheading:16184411...lld:pubmed
pubmed-article:16184411pubmed:year2005lld:pubmed
pubmed-article:16184411pubmed:articleTitleRebamipide, a gastro-protective drug, inhibits indomethacin-induced apoptosis in cultured rat gastric mucosal cells: association with the inhibition of growth arrest and DNA damage-induced 45 alpha expression.lld:pubmed
pubmed-article:16184411pubmed:affiliationMolecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan. ynaito@koto.kpu-m.ac.jplld:pubmed
pubmed-article:16184411pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16184411lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16184411lld:pubmed